Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 29.09% is 57% above its 5-year average of 18.54%, near the high end of its 5-year range (10.88%–29.09%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.01% above its 12-month average of 25.08%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 29.09%.
DEBT TO ASSETS RATIO
29.09%
DEBT TO ASSETS RATIO AVG TTM
25.08%
DEBT TO ASSETS RATIO AVG 3Y
20.95%
DEBT TO ASSETS RATIO AVG 5Y
18.54%
DEBT TO ASSETS RATIO AVG 10Y
16.94%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+16.01%
CURRENT VS 3Y AVG
+38.87%
CURRENT VS 5Y AVG
+56.89%
CURRENT VS 10Y AVG
+71.78%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+28994.24%
vs the sector median at left
Fate Therapeutics, Inc.
Market Cap
$272.17M
Debt to Assets Ratio
29.09%
TTM Avg
25.08%
3Y Avg
20.95%
5Y Avg
18.54%
Market Cap
$274.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$276.57M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.16M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.92M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.43M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$282.98M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.38M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.91M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $272.17M | 29.09% | 25.08% | 20.95% | 18.54% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.61M | 0.00% | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $276.57M | 0.04% | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | 0.01% | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | 0.02% | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $282.98M | 0.11% | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $284.38M | 0.01% | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $259.91M | 0.10% | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $286.20M | 0.03% | N/A | N/A | N/A |
Debt/Assets
29.1%
Debt/Equity
0.49
Current Ratio
4.85
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 29.09% |
| 2026-03-31 | 26.95% |
| 2025-12-31 | 24.41% |
| 2025-09-30 | 23.06% |
| 2025-06-30 | 21.88% |
| 2025-03-31 | 20.90% |
| 2024-12-31 | 19.35% |
| 2024-09-30 | 20.00% |
| 2024-06-30 | 19.02% |
| 2024-03-31 | 17.91% |
| 2023-12-31 | 20.45% |
| 2023-09-30 | 19.30% |
| 2023-06-30 | 18.19% |
| 2023-03-31 | 17.07% |
| 2022-12-31 | 15.50% |
| 2022-09-30 | 14.80% |
| 2022-06-30 | 13.92% |
| 2022-03-31 | 13.22% |
| 2021-12-31 | 12.46% |
| 2021-09-30 | 11.08% |
| 2021-06-30 | 10.88% |
| 2021-03-31 | 10.60% |
| 2020-12-31 | 15.63% |
| 2020-09-30 | 13.65% |
| 2020-06-30 | 12.40% |
| 2020-03-31 | 23.53% |
| 2019-12-31 | 8.91% |
| 2019-09-30 | 12.12% |
| 2019-06-30 | 21.31% |
| 2019-03-31 | 19.30% |
| 2018-12-31 | 6.99% |
| 2018-09-30 | 6.76% |
| 2018-06-30 | 17.85% |
| 2018-03-31 | 15.87% |
| 2017-12-31 | 14.06% |
| 2017-09-30 | 20.35% |
| 2017-06-30 | 9.03% |
| 2017-03-31 | 10.20% |
| 2016-12-31 | 11.24% |
| 2016-09-30 | 25.63% |
| 2016-06-30 | 29.57% |
| 2016-03-31 | 27.94% |
| 2015-12-31 | 26.84% |
| 2015-09-30 | 25.04% |
| 2015-06-30 | 23.59% |
| 2015-03-31 | 44.21% |
| 2014-12-31 | 38.33% |
| 2014-09-30 | 21.27% |
| 2014-06-30 | 1.71% |
| 2014-03-31 | 2.50% |
| 2013-12-31 | 3.12% |
| 2013-09-30 | 111.55% |
| 2013-06-30 | 43.87% |
| 2013-03-31 | 49.57% |
| 2012-12-31 | 33.16% |
